Portfoliotracker

enGene Therapeutics Inc.

ENGN · NASDAQCM · Healthcare Biotechnology 12/100 E

1,890 $
▼ −0,520 (−21,58 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 13:36
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score12 / 100 Market cap132 mil. $ P/E0,6 Forward P/E-1,2 P/S– P/B0,6 EV/EBITDA– Dividend yield– FCF yield-78,91 % EPS-2,07 $ Net margin0,0 % Return on equity-60,5 % Beta-0,24 Debt / equity0,14
52-week range 1,40 to 12,25
3-month average volume1,1 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.

Website
engene.com
Employees
81
Country
Canada
Fiscal year end
31. 10.
Data since
1. 2. 2022

Explore further

Similar companies LXEOPEPGKRROALMSCGON

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account